IJCRR - Vol 05 Issue 14, July, 2013
COMPARATIVE MOLECULAR MODELING STUDY OF BINDING OF MITOXANTRONE WITH D-(ATCGAT)2 AND D-(CTCGAG)2 HEXAMER DNA SEQUENCES
Author: Shilpa Dogra, Pamita Awasthi, Ritu Barthwal
Category: General Sciences
Mitoxantrone (MTX) - 1, 4–dihydroxy–5, 8–bis [[2–[2–hydroxyethyl) amino] amino]–9, 10–anthracenedione is, clinically well established anthracycline class of anticancer drug. Till today no structural details confirm the interaction of mitoxantrone with its receptor site i.e. DNA Although it has been proposed and confirmed that drug binds to DNA specifically at 5’-CpG-3’ site and flanking sequences play an important role. Also, functional group present on the tricyclic aromatic chromophore plays vital role in interactions. Molecular modeling tool has been applied to study binding interaction of mitoxantrone (MTX) with two hexameric DNA sequences i.e d-(ATCGAT)2, d-(CTCGAG)2 . The electrostatic interactions play a vital role in sequence specific identification at receptor site. Study indicates the partial intercalation of mitoxantrone into 5’-CpG-3’ base pair step while side chains at 5, 8 position interacts with backbone phosphate group futher stabilizes the complex. The conformation flexibility of the minimized complex is studied by backbone torsional angle as well helical parameters. It has been seen that MTX exhibit sequence specific binding. It is n+1, n+2, n+3/n-1, n-2/n-3 base pairs play important role in binding process. Studies propose the partial intercalation mode of binding.
Keywords: molecular modeling, DNA, mitoxantrone, hexamer sequences
Shilpa Dogra, Pamita Awasthi, Ritu Barthwal. COMPARATIVE MOLECULAR MODELING STUDY OF BINDING OF MITOXANTRONE WITH D-(ATCGAT)2 AND D-(CTCGAG)2 HEXAMER DNA SEQUENCES International Journal of Current Research and Review. Vol 05 Issue 14, July, 05-15
1. Murdock KC, Child RG, Fabio PF, Angier RB, Wallace TE, Durr FE, and Citarella RV, Antitumor Agents. 1, 4 Bis–[aminoalkyl) amino]–9,10 anthracenedione. J. Med. Chem., 1979, 22, 1024–1030.
2. Feofanov A, Sharonov S, Kudelina I, Fleury F, Nabiev I, Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis. J. Biophys., 1997, 73, 3317–3327.
3. Feofanov A, Sharonov S, Kudelina I, Fleury F, Nabiev, I, Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drugtarget complexes. J. Biophys., 1997, 73, 3328–3336.
4. Smith PJ, Morgan SA, Fox ME, Watson JV, Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem. Pharmacol., 1990, 40, 2069-2078.
5. D'Arpa P, Liu LF, Topoisomerase-targeting antitumor drugs. Biochem. Biophys. Acta. 1989, 989, 163-177.
6. Kapuscinski J, Darzynkiewicz Z, Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids. Proc. Natl. Acad. Sci., 1986, 83, 6302-6306.
7. Parker SB, Cutts MS, Cullinane C, Phillips RD, Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts. Nucleic. Acids Res., 2000, 28, 983–989.
8. Tarasiuk J, Tkaczyk-Gobis K, Stefanska B, Dzieduszycka M, Priebe W, Martelli S, Borowski E, The role of structural factors of anthraquinone compounds and their quinone-modified analogues in NADH dehydrogenase-catalysed oxygen radical formation. Anticancer Drug Des., 1998, 13, 923–939.
9. Lown JW, Hanstock CC, Bradley RD, Douglas GS, Interactions of Antitumor agents Mitoxantrone and Deoxyribonucleic Acids studied by electron Microscopy. Molecular Pharma., 1983, 25, 178–184.
10. Lown JW, Morgan AR, Yen Shau–Fong, Wang Yueh–Hwa, Wilson WD, Characterization of binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry. 1985, 24, 4028–4035.
11. Tanious FA, Jenkins TC, Neidle S, Wilson WD, Substituent position dictates the intercalative DNA–Binding mode for anthracene 9, 10–dione antitumor drugs. Biochemistry, 1992, 31, 11632–11640.
12. Kapuscinski J, Darzynkiewicz Z, Interactions of antitumor agents ametantrone and mitoxantrone (novantrone) with double– stranded DNA. Biochem Pharmacol., 1985, 34, 4203–4213.
13. Lown, JW, Hanstock CC, High field 1H– NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]. J. Biomol. Struct. Dyn., 1985, 2, 1097-1106.
14. Kotovych, G, Lown JW, Tong KPJ, High field 1H and 31P NMR studies on the binding of the anticancer agent mitoxantrone to d– [CpGpApTpCpG)2. J. Biomol. Struct. Dyn., 1986, 4, 111-125.
15. Panousis C, Phillips DR, Sequence specificity of Mitoxantrone. Nucleic Acids Res., 1994, 22, 1342–1345.
16. Parker SB, Cutts SM, Phillips RD, Cytosine Methylation Enhances Mitoxantrone-DNA Adduct Formation at CpG Dinucleotides. J Biol. Chem., 2001, 276, 15953-15960.
17. Davies DB, Veselkov DA, Evstigneev MP, Veselkov AN, Self–association of the antitumour agent novatrone (mitoxantrone) and its hetero–association with caffeine. J Chem. Soc. Perkin Trans, 2001, 2, 61–67.
18. Davies DB, Veselkov DA, Djimant LN, Veselkov AN, Hetero–association of caeffine and aromatic drugs and their competitive binding with DNA oligomer. J Eur. Biophys. 2001, 30, 354–356.
19. Veselkov AN, Evstigneev MP, Vysotskii SA, Veseklov DA, Davies DB, Thermodynamic analysis of interaction of antibiotic mitoxantrone with tetranucleotide 5’–d (TpGpCpA) in aqueous solution based on 1H NMR spectroscopy data. Biofizika 2002, 47, 432–438.
20. Zheng S, Chen Yu, Donahue CP, Wolfe MS, Varani G, Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novatrone (mitoxantrone). Chem Biol., 2009, 16, 557-566.
21. Chen XK, Gresh N, Pullman B, Nucl. A theoretical investigation on the sequence selective binding of mitoxantrone to double– stranded tetranucleotides. Nucleic Acids Res., 1986, 14, 3799-3812.
22. Riahi S, Ganjali RM, Dinarvand R, Karamdoust S, Bagherzadeh K, Norouzi PA, Theoretical Study on Interactions Between Mitoxantrone as an Anticancer Drug and DNA. Chem. Biol. Drug Des., 2008, 7, 474– 482.
23. Parker BS, Buley T, Evinson B, Cutts SM, Neumann GM, Iskander MN,. Phillips DR, Molecular understandings of mitoxantrone– DNA adduct formation: Effect of cytosine methylation and flanking sequences. J Biol. Chem., 2004, 279, 18814–18823.
24. Rehn C, Pindur U, Model Building and Molecular Mechanics Calculations of Mitoxantrone-Deoxytetranucleotide Complexes: Molecular Foundations of D N A Intercalation as Cytostatic Active Principle. Monatsh chemie., 1996, 127, 631- 644.
25. Awasthi P, Dogra S, Awasthi LK and Barthwal R, Software Tools and Algorithms for Biological System, Advances in Experimental Medicine and Biology, in: H.R Arabnia and Q.-N. Tran (eds.), New York, Springer, 2011, 39, 385-400.
26. Bailly C, Routier, S, Bernier J. -L and Waring M. J, DNA recognition by two mitoxantrone analogues: influence of the hydroxyl groups. FEBS Letters, 1996, 379 269-272.
27. Schneider B, Neidle S, Berman HM, Conformations of the sugar-phosphate backbone in helical DNA crystal structures. Biopolymers, 1997, 42, 113-124.
28. Lam, S. L. and Au-Yeung, S. C. F. Sequence-specific Local Structural Variations in Solution Structures of d(CGXX0CG)2 and d(CAXX0TG)2 Selfcomplementary Deoxyribonucleic Acids. J. Mol. Biol., 1997, 266, 745-760